JPH0920611A - Skin preparation for external use - Google Patents
Skin preparation for external useInfo
- Publication number
- JPH0920611A JPH0920611A JP18813095A JP18813095A JPH0920611A JP H0920611 A JPH0920611 A JP H0920611A JP 18813095 A JP18813095 A JP 18813095A JP 18813095 A JP18813095 A JP 18813095A JP H0920611 A JPH0920611 A JP H0920611A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- acid
- effect
- present
- tranexamic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 claims abstract description 42
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 22
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 22
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960003951 masoprocol Drugs 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 abstract description 36
- -1 vitamin ester Chemical class 0.000 abstract description 12
- 230000019612 pigmentation Effects 0.000 abstract description 7
- 206010013786 Dry skin Diseases 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 206010015150 Erythema Diseases 0.000 abstract description 2
- 231100000321 erythema Toxicity 0.000 abstract description 2
- 229910052751 metal Inorganic materials 0.000 abstract description 2
- 239000002184 metal Substances 0.000 abstract description 2
- 230000002062 proliferating effect Effects 0.000 abstract description 2
- 229930003231 vitamin Natural products 0.000 abstract description 2
- 239000011782 vitamin Substances 0.000 abstract description 2
- 235000013343 vitamin Nutrition 0.000 abstract description 2
- 229940088594 vitamin Drugs 0.000 abstract description 2
- 150000004370 vitamin A ester derivatives Chemical class 0.000 abstract description 2
- 241001517988 Pachymenia Species 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 230000001496 desquamative effect Effects 0.000 abstract 1
- 230000037336 dry skin Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 49
- 239000006210 lotion Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 230000002087 whitening effect Effects 0.000 description 8
- 208000012641 Pigmentation disease Diseases 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000007788 roughening Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 239000004200 microcrystalline wax Substances 0.000 description 2
- 235000019808 microcrystalline wax Nutrition 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940027041 8-mop Drugs 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000019028 Epidermal thickening Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は皮膚外用剤に関する。さ
らに詳しくは、肌荒れを防止、改善し、また皮膚に対す
る美白効果に優れた安全性の高い皮膚外用剤に関する。FIELD OF THE INVENTION The present invention relates to a skin external preparation. More specifically, the present invention relates to a highly safe external preparation for skin which prevents and improves rough skin and has an excellent whitening effect on the skin.
【0002】[0002]
【従来の技術】皮膚外用剤には種々の薬効成分が配合さ
れている。その中で、肌荒れ防止、肌荒れ改善効果も皮
膚外用剤に要求される薬効の一つであり、これを目的と
する化粧品等の皮膚外用剤が要求されていた。こうした
中で、従来は、天然物から抽出した各種原料、例えばタ
ンパク質、多糖、抽出エキス、天然高分子等がその使用
効果が特徴的であるため皮膚外用剤に配合されてきた。2. Description of the Related Art Various external medicines have been incorporated into external preparations for skin. Among them, the skin roughening prevention and skin roughening improving effects are also one of the medicinal effects required of external skin preparations, and the external skin preparations such as cosmetics for this purpose have been demanded. Under these circumstances, various raw materials extracted from natural products, such as proteins, polysaccharides, extracted extracts, and natural polymers, have conventionally been blended in the skin external preparation because of their characteristic use effects.
【0003】また、美白効果も皮膚外用剤に要求される
薬効の一つである。皮膚のしみなどの発生機序について
は不明な点もあるが、一般的には、ホルモンの異常や日
光からの紫外線の刺激が原因となってメラニン色素が形
成され、これが皮膚内に異常沈着するするものと考えら
れている。このようなしみやあざの治療法には、メラニ
ンの生成を抑制する物質、例えばビタミンCを大量に投
与する方法、グルタチオン等を注射する方法、あるいは
L−アルコルビン酸、システインなどを軟膏、クリー
ム、ローションなどの形態にして、局所に塗布するなど
の方法がとられている。A whitening effect is also one of the medicinal effects required for external preparations for skin. Although there are some unclear points regarding the mechanism of skin stains and the like, in general, melanin pigment is formed due to hormonal abnormalities and irritation of ultraviolet rays from sunlight, and this causes abnormal deposition in the skin. It is thought to do. Such a method for treating spots and bruises includes a substance that suppresses the production of melanin, for example, a method of administering a large amount of vitamin C, a method of injecting glutathione, etc., or an ointment, cream, lotion of L-alcorbic acid, cysteine, etc. In such a form, a method of applying it locally is adopted.
【0004】[0004]
【発明が解決しようとする課題】しかしながら、その効
果は十分とは言えず、より優れた効果のある皮膚外用剤
の開発が待望されていた。However, the effect is not sufficient, and there has been a long-awaited development of a skin external preparation having more excellent effect.
【0005】本発明者等は、上記事情に鑑み、安全性に
優れた物質の中から特に肌荒れを防止し、肌荒れを改善
する効果に優れ、さらに美白効果をも有する物質を得る
べく鋭意研究を重ねた結果、トラネキサム酸、もしくは
その塩類、もしくはその誘導体から選ばれる一種または
二種以上と、ノルジヒドログアイアレチン酸とを配合す
ることにより、増殖性の表皮肥厚、紅斑を伴う乾燥、落
屑性の変化に対して極めて有効であり、さらに色素沈着
をも有効に防止、改善出来る皮膚外用剤が得られること
を見い出し本発明を完成するに至った。In view of the above circumstances, the inventors of the present invention have earnestly studied in order to obtain a substance that is excellent in the effect of preventing rough skin and improving rough skin, and also having a whitening effect, among substances having excellent safety. As a result of overlapping, by blending one or more selected from tranexamic acid, or a salt thereof, or a derivative thereof, and nordihydroguaiaretic acid, proliferative epidermal thickening, dryness with erythema, and desquamation It was found that a skin external preparation that is extremely effective against changes in the above-mentioned and that can also effectively prevent and improve pigmentation is obtained, and completed the present invention.
【0006】本発明の目的は肌荒れ防止、肌荒れ改善効
果に優れ、さらに美白効果をも併せ持った皮膚外用剤を
提供することにある。An object of the present invention is to provide an external preparation for skin which is excellent in the effects of preventing rough skin and improving rough skin, and also has a whitening effect.
【0007】[0007]
【課題を解決するための手段】すなわち、本発明は、ト
ラネキサム酸、もしくはその塩類、もしくはその誘導体
から選ばれる一種または二種以上と、ノルジヒドログア
イアレチン酸とを含有することを特徴とする皮膚外用剤
を提供するものである。That is, the present invention is characterized by containing nordihydroguaiaretic acid and one or more selected from tranexamic acid, salts thereof, or derivatives thereof. An external preparation for skin is provided.
【0008】また、本発明は、上記トラネキサム酸、も
しくはその塩類、もしくはその誘導体から選ばれる一種
または二種以上を0.1〜5.0重量%含有し、かつ上
記記ノルジヒドログアイアレチン酸を0.01〜5.0
重量%含有することを特徴とする上記記載の皮膚外用剤
を提供するものである。The present invention also contains 0.1 to 5.0% by weight of one or more selected from the above tranexamic acid, salts thereof, or derivatives thereof, and the above nordihydroguaiaretic acid. 0.01 to 5.0
The external preparation for skin according to the above is characterized in that it is contained in a weight percentage.
【0009】以下、本発明の構成について詳述する。本
発明で用いられるトラネキサム酸、もしくはその塩類、
もしくはその誘導体は、抗プラスミン剤として一般に用
いられており、化粧品用途では、安全性が高いことを特
徴とする成分として知られている(特開昭42−369
80号公報)。The structure of the present invention will be described in detail below. Tranexamic acid used in the present invention, or a salt thereof,
Alternatively, a derivative thereof is generally used as an antiplasmin agent and is known as a component characterized by high safety in cosmetic use (JP-A-42-369).
No. 80).
【0010】また、その製造法は、特許第230611
号公報、特許第242664号公報、特許第48041
1号公報、特許第488168号公報によって知られて
いる。The manufacturing method is disclosed in Japanese Patent No. 230611.
Japanese Patent, Japanese Patent No. 242664, Japanese Patent No. 48041
It is known from Japanese Patent No. 1 and Japanese Patent No. 488168.
【0011】トラネキサム酸は、融点386〜390
℃、白色の結晶又は粉末で、臭いはなく、味は苦い。ト
ラネキサム酸の塩は、通常使用される塩として、Mg、
Ca、K等の金属塩、硫酸塩等があり、誘導体として
は、ビタミンAエステル、ビタミンEエステル、ビタミ
ンCエステル、ビタミンDエステル等のビタミンエステ
ル類、N,N-マレオイルミノトラネキサム酸等が挙げられ
るが、本発明はこれらに限定されるものではない。Tranexamic acid has a melting point of 386-390.
C, white crystals or powder, odorless, taste bitter. The salt of tranexamic acid is Mg, which is a commonly used salt.
There are metal salts such as Ca and K, sulfates, and the like, and as the derivatives, vitamin esters such as vitamin A ester, vitamin E ester, vitamin C ester, and vitamin D ester, and N, N-maleoylminotranexamic acid. However, the present invention is not limited thereto.
【0012】本発明においては、上記トラネキサム酸、
もしくはその塩類、もしくはその誘導体のなかから一種
又は二種以上が任意に選ばれて用いられ、その配合量
は、皮膚外用剤全量中、0.01〜10.0重量%が好
ましく、0.1〜5.0重量%が更に好ましい。0.0
1重量%未満では本発明の十分な肌荒れ防止・改善効果
及び美白効果が得られず、10.0重量%を越えて加え
てもそれ以上の効果は得られない。In the present invention, the above tranexamic acid,
Alternatively, one kind or two or more kinds are arbitrarily selected and used from the salts or the derivatives thereof, and the compounding amount thereof is preferably 0.01 to 10.0% by weight in the total amount of the external preparation for skin, and 0.1% by weight is preferable. It is more preferably ˜5.0% by weight. 0.0
If the amount is less than 1% by weight, the effect of preventing and improving skin roughness and the whitening effect of the present invention cannot be sufficiently obtained, and if the amount exceeds 10.0% by weight, no further effect can be obtained.
【0013】本発明に使用するノルジヒドログアイアレ
チン酸は下記式で表される物質である。The nordihydroguaiaretic acid used in the present invention is a substance represented by the following formula.
【化1】 Embedded image
【0014】上記のノルジヒドログアイアレチン酸は、
一般には、抗酸化剤やリポキシゲナーゼ阻害剤として知
られている物質である。これまでにも、不飽和脂肪酸の
酸化防止剤や薬剤の安定化剤として、また酸化防止や薬
剤安定化を目的として、化粧品、育毛料、歯磨剤、医薬
品などに応用されている物質である(特開平4−217
626号公報、特開平3−20205号公報、特開昭6
1−238718号公報、特開昭61−238715号
公報)。The above-mentioned nordihydroguaiaretic acid is
Generally, it is a substance known as an antioxidant or a lipoxygenase inhibitor. So far, it is a substance that has been applied to cosmetics, hair restorers, dentifrices, pharmaceuticals, etc. as an antioxidant of unsaturated fatty acids and a stabilizer of drugs, and for the purpose of antioxidant and drug stabilization ( Japanese Patent Laid-Open No. 4-217
626, JP 3-20205 A, JP 6
No. 1-238718, JP-A-61-238715).
【0015】本発明においてノルジヒドログアイアレチ
ン酸の皮膚外用剤への配合量は、組成物全量中0.01
〜10.0重量%が好ましく、0.01〜5.0重量%
がより好ましい。0.01重量%未満では本発明の効果
が十分でなく、10.0重量%を越えると製剤上好まし
くなく、かつ不経済である。In the present invention, the amount of nordihydroguaiaretic acid added to the external skin preparation is 0.01 based on the total amount of the composition.
~ 10.0% by weight is preferred, 0.01-5.0% by weight
Is more preferred. If it is less than 0.01% by weight, the effect of the present invention is not sufficient, and if it exceeds 10.0% by weight, it is not preferable in terms of formulation and it is uneconomical.
【0016】本発明においては、上記トラネキサム酸、
もしくはその塩類、もしくはその誘導体から選ばれる一
種または二種以上と、ノルジヒドログアイアレチン酸と
を併用して用いることで、肌荒れ防止、改善効果および
美白効果をより向上させることができる。In the present invention, the above tranexamic acid,
Alternatively, the combined use of nordihydroguaiaretic acid with one or two or more selected from salts or derivatives thereof can further improve the prevention of rough skin, the improving effect and the whitening effect.
【0017】本発明の皮膚外用剤は前記の必須成分に加
えて、必要に応じ、本発明の効果を損なわない範囲内
で、化粧料、医薬部外品、医薬品等に一般的に用いられ
る各種成分、水性成分、保湿剤、増粘剤、紫外線吸収
剤、防腐剤、酸化防止剤、香料、色剤、薬剤、生薬等を
配合することができる。In addition to the above-mentioned essential components, the external preparation for skin of the present invention is, if necessary, within the range that does not impair the effects of the present invention, and is generally used in cosmetics, quasi drugs, pharmaceuticals, etc. Ingredients, aqueous ingredients, moisturizers, thickeners, ultraviolet absorbers, preservatives, antioxidants, fragrances, colorants, drugs, crude drugs and the like can be added.
【0018】また、本発明の皮膚外用剤の剤型は任意で
あり、例えば、化粧水等の可溶化系、乳液、クリーム等
の乳化系、あるいは軟膏、粉末分散系、水−油ニ層系、
水−油−粉末三層系等、どのような剤型でもかまわな
い。The dosage form of the external preparation for skin of the present invention is arbitrary. For example, a solubilizing system such as lotion, an emulsifying system such as emulsion or cream, or an ointment, powder dispersion system, water-oil two-layer system. ,
Any formulation such as water-oil-powder three-layer system may be used.
【0019】[0019]
【実施例】次に実施例をあげて本発明を詳細に説明する
が、本発明の技術範囲がこれらの実施例に限定されるも
のではないことはいうまでもない。なお、実施例中の配
合量は重量%である。実施例に先立ち、本発明で用いた
試験法、評価法を説明する。EXAMPLES Next, the present invention will be described in detail with reference to examples, but it goes without saying that the technical scope of the present invention is not limited to these examples. The blending amount in the examples is% by weight. Prior to the examples, test methods and evaluation methods used in the present invention will be described.
【0020】発明に係わる皮膚外用剤の外皮適用による
効果を、肌荒れ、カミソリ負け及び色素沈着に対する改
善率から評価した。The effect of external skin application of the skin external preparation according to the present invention was evaluated from the improvement rate for rough skin, razor loss and pigmentation.
【0021】〔肌荒れ改善効果試験〕肌荒れあるいは日
焼け後の肌のほてりの病状で悩む被験者各60名で実施
し、「表1」に示す実施例1及び比較例1〜3の組成の
ローションを顔面に塗布し、2週間後肌状態を目視で判
定した。また、カミソリ負けする男性被験者60名を対象
にひげ剃り直後に「表1」に示す実施例1及び比較例1
〜3の組成のロ−ションを塗布し、カミソリ負けに対す
る効果を判定した。各判定基準は以下の通りとした。[Skin Roughness Improvement Effect Test] 60 lots of subjects suffering from skin roughening or hot flashes after sunburn were carried out on each of 60 subjects, and lotions having the compositions of Example 1 and Comparative Examples 1 to 3 shown in “Table 1” were applied to the face. After 2 weeks, the skin condition was visually evaluated. In addition, Example 1 and Comparative Example 1 shown in "Table 1" immediately after shaving were performed on 60 male subjects who lost razors.
A lotion having a composition of ˜3 was applied and the effect on razor loss was evaluated. Each criterion was as follows.
【0022】「肌荒れに対する改善効果」 著効:症状の消失したもの 有効:症状の弱くなったもの やや有効:症状がやや弱くなったもの 無効:症状に変化を認めないもの"Amelioration effect on rough skin" Remarkable effect: symptom disappeared Effective: symptom weakened somewhat effective: symptom slightly weakened Ineffective: symptom unchanged
【0023】「カミソリ負けに対する改善効果」 著効:カミソリ負けの消失したもの 有効:カミソリ負けの弱くなったもの やや有効:カミソリ負けがやや弱くなったもの 無効:カミソリ負けに変化を認めないもの"Effect of improving razor loss" Remarkable effect: razor loss of loss Effective: razor loss of weakness Some effect: razor loss of weakness Invalid: razor loss of no change
【0024】(判定) ◎:被験者が著効、有効及びやや有効を示す割合(有効
率)が80%以上 ○:被験者が著効、有効及びやや有効を示す割合(有効
率)が50%以上〜80%未満 △:被験者が著効、有効及びやや有効を示す割合(有効
率)が30%以上〜50%未満 ×:被験者が著効、有効及びやや有効を示す割合(有効
率)が30%未満(Judgment) ⊚: The rate at which the test subject is markedly effective, effective and slightly effective (effective rate) is 80% or more. ◯: The ratio at which the test subject is markedly effective, effective and slightly effective (effective rate) is 50% or more. 〜Less than 80% △: The rate at which the subject is markedly effective, effective and slightly effective (effective rate) is 30% or more and less than 50% ×: the rate at which the subject is markedly effective, effective and slightly effective (effective rate) is 30 %Less than
【0025】[0025]
【表1】 [Table 1]
【0026】[0026]
【表2】 [Table 2]
【0027】「表2」から明らかなように、トラネキサ
ム酸とノルジヒドログアイアレチン酸を配合する本発明
の実施例1のローションは、ブランクの比較例1、比較
例2、比較例3のローションより、肌荒れ、カミソリ負
けにたいして優れた改善効果を示した。As is clear from Table 2, the lotions of Example 1 of the present invention containing tranexamic acid and nordihydroguaiaretic acid are blank lotions of Comparative Example 1, Comparative Example 2 and Comparative Example 3. As a result, it showed an excellent improving effect against rough skin and razor loss.
【0028】〔肌荒れ改善効果〕実施例1と比較例1〜
3のローションを用いて、人体パネルで肌荒れ改善効果
試験を行った。即ち、女性健常人(顔面)の皮膚表面形
態をミリスン樹脂によるレプリカ方を用いて肌のレプリ
カを取り、顕微鏡(17倍)にて観察した。皮紋の状態及
び角層の剥離状態から「表3」に示す基準に基づいて肌
荒れ評価1、2と判断されたもの(肌荒れパネル)20
名を用い、顔面左右半々に、実施例1と比較例1〜3の
ローションを1日1回2週間塗布した。2週間後、再び
上述のレプリカ法にしたがって肌の状態を観察し、「表
3」の判定基準にしたがって評価した。その結果を「表
4」に示す。[Effect of Roughness of Skin] Example 1 and Comparative Examples 1 to 1
A lotion of 3 was used to perform a skin roughening improvement effect test on a human body panel. That is, the skin surface morphology of a healthy female person (face) was taken using a replica method using myrisin resin, and the skin was taken and observed under a microscope (17 times). What was judged to be rough skin evaluation 1 or 2 based on the criteria shown in "Table 3" based on the condition of the skin print and the peeling condition of the stratum corneum (rough skin panel) 20
The lotions of Example 1 and Comparative Examples 1 to 3 were applied to the left and right half of the face once a day for 2 weeks. Two weeks later, the skin condition was observed again according to the above-mentioned replica method, and evaluated according to the criteria of "Table 3". The results are shown in "Table 4".
【0029】[0029]
【表3】 [Table 3]
【0030】[0030]
【表4】 [Table 4]
【0031】「表4」から判るように、本発明の実施例
1のローションは、比較例1〜3のローションと比較
し、顕著な肌荒れ改善効果が認められた。As can be seen from "Table 4", the lotion of Example 1 of the present invention was found to have a remarkable effect of improving rough skin as compared with the lotions of Comparative Examples 1 to 3.
【0032】〔色素沈着効果及び副作用〕8-MOP処理
光毒性色素沈着Weiser Maple GPを用いて、毛刈りし
た背部に50μlのテストサンプルを1日1回約4cm2の範
囲に8週間塗布し、抗色素沈着効果及び副作用として現
れた色素増強の程度を「表5」に示した4点評価法(+
の評価点は脱色効果、−の評価点は副作用)にて表し
た。使用サンプルはアスコルビン1%酸溶液と、トラネ
キサム酸1%とノルジヒドログアイアレチン酸1%の混合
溶液(本発明品)を用いた。その結果を表6に示す。[Pigmentation Effect and Side Effects] 8-MOP-treated phototoxic pigmentation Weiser Maple GP was used to apply 50 μl of the test sample to the shaved back once a day in the range of about 4 cm 2 for 8 weeks, The four-point evaluation method (+
The evaluation score of (-) is represented by the decolorizing effect, and the evaluation score of-is represented by side effect). The sample used was an ascorbine 1% acid solution and a mixed solution of 1% tranexamic acid and 1% nordihydroguaiaretic acid (invention product). Table 6 shows the results.
【0033】[0033]
【表5】 [Table 5]
【0034】[0034]
【表6】 [Table 6]
【0035】「表6」から明らかなように、アスコルビ
ン酸は長期連用により、副作用として色素沈着が起こる
のに対し、トラネキサム酸とノルジヒドログアイアレチ
ン酸の混合溶液は脱色効果が優れるとともに、長期連用
による副作用を生じなかった。As is clear from "Table 6", long-term continuous use of ascorbic acid causes pigmentation as a side effect, whereas a mixed solution of tranexamic acid and nordihydroguaiaretic acid has an excellent decolorizing effect and a long-term effect. There were no side effects from repeated use.
【0036】〔実使用試験〕顔面に色素沈着症を有する
被験者100名のパネルとして、各々25名ずつに、実
施例1及び比較例1〜3を、1日に2〜3回顔面に使用
させ、3カ月連続使用後、医師により肉眼で淡色化効果
の判定を行った。 「表7」に示した結果から明らかな
ように、トラネキサム酸とノルジヒドログアイアレチン
酸を配合した実施例1の抗色素沈着剤は、雀卵斑、肝
斑、老人性色素斑等、多種の色素沈着症に著しい効果を
有することが示唆された。[Actual Use Test] As a panel of 100 subjects with facial pigmentation, 25 subjects each were allowed to use Example 1 and Comparative Examples 1 to 3 on the face 2-3 times a day. After 3 consecutive months of use, the doctor judged the lightening effect with the naked eye. As is clear from the results shown in "Table 7", the anti-pigmenting agent of Example 1 containing tranexamic acid and nordihydroguaiaretic acid was mixed in various types such as sporadic egg spots, melasma, and senile pigment spots. It was suggested that it has a remarkable effect on the pigmentation disease.
【0037】[0037]
【表7】 [Table 7]
【0038】以下の実施例2〜6の組成で常法により各
皮膚外用剤を製造したところ、いずれも良好な肌荒れ防
止・改善効果及び美白効果が得られた。When each of the external preparations for skin was prepared by the conventional method with the compositions of Examples 2 to 6 below, good effects of preventing and improving rough skin and whitening effects were obtained.
【0039】 実施例2 化粧水 重量% トラネキサム酸 5.0 ノルジヒドログアイアレチン酸 0.01 グリセリン 1.0 エタノール 7.0 ポリオキシエチレン(20モル)オレイルアルコールエーテル 0.5 メチルパラベン 0.05 クエン酸 0.01 クエン酸ナトリウム 0.1 香料 0.01 精製水 残部Example 2 Skin Lotion Wt% tranexamic acid 5.0 nordihydroguaiaretic acid 0.01 glycerin 1.0 ethanol 7.0 polyoxyethylene (20 mol) oleyl alcohol ether 0.5 methylparaben 0.05 citric acid 0.01 sodium citrate 0.1 perfume 0.01 purified water balance
【0040】 実施例3 クリーム 重量% セトステアリルアルコール 3.5 スクワラン 30.0 ミツロウ 3.0 還元ラノリン 5.0 エチルパラベン 0.3 ポリオキシエチレン(20モル)オレイルアルコールエーテル 2.0 ステアリン酸モノグリセリド 2.0 トラネキサム酸 3.0 ノルジヒドログアイアレチン酸 3.0 グリセリン 15.0 香料 0.03 精製水 残部Example 3 Cream wt% cetostearyl alcohol 3.5 Squalane 30.0 Beeswax 3.0 Reduced lanolin 5.0 Ethylparaben 0.3 Polyoxyethylene (20 mol) oleyl alcohol ether 2.0 Stearic acid monoglyceride 2.0 Tranexamic acid 3.0 Nordihydroguaiaretic acid 3.0 Glycerin 15.0 Fragrance 0.03 Purified water balance
【0041】 実施例4 パック 重量% トラネキサム酸 10.0 ノルジヒドログアイアレチン酸 5.0 ポリビニルアルコール 10.9 プロピレングリコール 7.0 エタノール 10.0 メチルパラベン 0.05 香料 0.05 精製水 残部Example 4 Pack weight% Tranexamic acid 10.0 Nordihydroguaiaretic acid 5.0 Polyvinyl alcohol 10.9 Propylene glycol 7.0 Ethanol 10.0 Methylparaben 0.05 Perfume 0.05 Purified water balance
【0042】 実施例5 口紅 重量% マイクロクリスタリンワックス 1.0 ミツロウ 2.0 ラノリン 2.0 流動パラフィン 20.0 スクワラン 10.0 ソルビタンセスキオレイン酸エステル 4.0 ポリオキシエチレン(20モル)ソルビタンモノオレイン酸エステル 4.0 トラネキサム酸 0.5 ノルジヒドログアイアレチン酸 0.01 防腐剤・酸化防止剤 適量 香料 適量 精製水 残部Example 5 Lipstick wt% Microcrystalline wax 1.0 Beeswax 2.0 Lanolin 2.0 Liquid paraffin 20.0 Squalane 10.0 Sorbitan sesquioleate 4.0 Polyoxyethylene (20 mol) sorbitan monooleate 4.0 Tranexamic acid 0.5 Nordihydroguaiaretic acid 0.01 Preservative / antioxidant Appropriate amount Perfume Appropriate amount Purified water Balance
【0043】 実施例6 化粧水 重量% 95%エタノール 25.0 ポリオキシエチレン(40モル)硬化ひまし油 4.0 防腐剤・酸化防止剤 適量 香料 適量 ジプロピレングリコール 12.0 グリセリン 5.0 アラビトール 7.0 トラネキサム酸 0.1 ノルジヒドログアイアレチン酸 10.0 イオン交換水 残部Example 6 Lotion lotion 95% Ethanol 25.0 Polyoxyethylene (40 mol) hydrogenated castor oil 4.0 Preservative / antioxidant Appropriate amount Perfume Appropriate amount Dipropylene glycol 12.0 Glycerin 5.0 Arabitol 7.0 Tranexamic acid 0.1 Nordihydroguaiaretic acid 10.0 Deionized water balance
【0044】 実施例7 口紅 重量% マイクロクリスタリンワックス 1.0 ミツロウ 2.0 ラノリン 2.0 流動パラフィン 20.0 スクワラン 10.0 ソルビタンセスキオレイン酸エステル 4.0 ポリオキシエチレン(20モル)ソルビタンモノオレイン酸エステル 4.0 トラネキサム酸 0.01 ノルジヒドログアイアレチン酸 0.01 防腐剤・酸化防止剤 適量 香料 適量 精製水 残部Example 7 Lipstick wt% Microcrystalline wax 1.0 Beeswax 2.0 Lanolin 2.0 Liquid paraffin 20.0 Squalane 10.0 Sorbitan sesquioleate 4.0 Polyoxyethylene (20 mol) sorbitan monooleate 4.0 Tranexamic acid 0.01 Nordihydroguaiaretic acid 0.01 Preservative / antioxidant Appropriate amount Perfume Appropriate amount Purified water Balance
【0045】[0045]
【発明の効果】本発明の皮膚外用剤は、肌荒れ防止、改
善効果に優れ、また皮膚に対する美白効果にも優れる安
全性の高いものであった。EFFECTS OF THE INVENTION The external preparation for skin of the present invention is excellent in the effects of preventing and improving rough skin, and also in the effect of whitening the skin, and is highly safe.
フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 C07C 39/16 C07C 39/16 229/46 9450−4H 229/46 Continuation of the front page (51) Int.Cl. 6 Identification code Office reference number FI Technical display area C07C 39/16 C07C 39/16 229/46 9450-4H 229/46
Claims (2)
しくはその誘導体から選ばれる一種または二種以上と、
ノルジヒドログアイアレチン酸とを含有することを特徴
とする皮膚外用剤。1. One or more selected from tranexamic acid, salts thereof, or derivatives thereof,
A skin external preparation containing nordihydroguaiaretic acid.
類、もしくはその誘導体から選ばれる一種または二種以
上を0.1〜5.0重量%含有し、かつ前記ノルジヒド
ログアイアレチン酸を0.01〜5.0重量%含有する
ことを特徴とする請求項1記載の皮膚外用剤。2. 0.1 to 5.0% by weight of one or more selected from the above tranexamic acid, salts thereof, or derivatives thereof, and 0.01 to 5.0 of the nordihydroguaiaretic acid. The external preparation for skin according to claim 1, which contains 5.0% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18813095A JPH0920611A (en) | 1995-06-30 | 1995-06-30 | Skin preparation for external use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18813095A JPH0920611A (en) | 1995-06-30 | 1995-06-30 | Skin preparation for external use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0920611A true JPH0920611A (en) | 1997-01-21 |
Family
ID=16218260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP18813095A Withdrawn JPH0920611A (en) | 1995-06-30 | 1995-06-30 | Skin preparation for external use |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0920611A (en) |
-
1995
- 1995-06-30 JP JP18813095A patent/JPH0920611A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2764510B2 (en) | Whitening cosmetics | |
| KR20180027375A (en) | Compositions for Moisturizing Skin Containing Vegetable Vernix Ingredients | |
| JP2025083496A (en) | Cosmetic compositions comprising sucrose esters and solvents | |
| JPH08133952A (en) | Skin preparation for external use | |
| JP4424561B2 (en) | Whitening cosmetics | |
| JPH11510824A (en) | Cosmetic method for treatment and prevention of signs of skin aging | |
| JP3434911B2 (en) | External preparation for skin | |
| JPH09255551A (en) | Skin preparation for external use | |
| JPH05201847A (en) | Skin-beautifying cosmetic | |
| JP2005519935A (en) | Compositions and methods for the delivery of dermatological cosmetics | |
| JP2008247787A (en) | Skin preparation | |
| CN101198377B (en) | Cosmetic composition for removing spots or whitening skin containing at least one oxazoline as active ingredient | |
| JP2002114629A (en) | Cosmetic | |
| JP2002128654A (en) | Skin care preparation | |
| JP3001121B2 (en) | External preparation for skin | |
| JPH0920611A (en) | Skin preparation for external use | |
| JP2003238429A (en) | Fibroblast cell-activating agent and skin external agent containing the same | |
| JPH07149622A (en) | Beautifying and whitening preparation | |
| JPH09309841A (en) | Preparation for external use for skin | |
| JP2002121110A (en) | Cosmetic | |
| JP2001270828A (en) | External preparation for prevention and therapy of vulgaris acne and cosmetic prepared by formulating the same | |
| JPH0692833A (en) | Skin external agent | |
| JPH10273424A (en) | Cosmetic for hair | |
| JPH05213735A (en) | Beautifully whitening cosmetic | |
| JPH07215832A (en) | Skin external preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Withdrawal of application because of no request for examination |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20020903 |